Express2 Revises Boston Scientific’s U.S. Stent Sales; Japan Nir Sales Sag
This article was originally published in The Gray Sheet
Executive Summary
Rapid uptake of the Express2 stent confirms Boston Scientific's expectation that the internally developed platform will revitalize its languishing stent business as the company awaits the introduction of a drug-eluting counterpart
You may also be interested in...
Boston Scientific Cuts Medinol Ties With Express2 Stent Approval In U.S.
Boston Scientific will no longer depend on Israeli firm Medinol for its coronary stents in the U.S. after gaining FDA approval of its Express2 stent Sept. 12
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.